The impact of HFD CTD-002-treated HFD-fed SD rats showed a significant reduction in the amount of fat vesicles relative to control HFD-fed rats, demonstrating the therapeutic benefit of extracellular CTSD inhibition in the context of hepatic steatosis, a main feature of NAFLD (Figure 3A). This evidence concerns the gene CTSD and fatty liver disease.